Literature DB >> 9747722

Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.

Y Chen1, S J Ghim, A B Jenson, R Schlegel.   

Abstract

Recently, the L1 capsid protein of canine oral papillomavirus (COPV) has been used as an effective systemic vaccine that prevents viral infections of the oral mucosa. The efficacy of this vaccine is critically dependent upon native L1 conformation and, when purified from Sf9 insect cells, the L1 protein not only displays type-specific, conformation-dependent epitopes but it also assembles spontaneously into virus-like particles (VLPs). To determine whether VLP formation was coupled to the expression of conformation-dependent epitopes, we generated a series of N- and C-terminal L1 deletion mutants and evaluated their ability to form VLPs (by electron microscopy) and to react with conformation-dependent antibodies (by immunofluorescence microscopy). We found that (a) deletion of the 26 C-terminal residues generated a mutant protein which formed VLPs efficiently and folded correctly both in the cytoplasm and in the nucleus; (b) further truncation of the L1 C terminus (67 amino acids) resulted in a capsid protein which formed VLPs but which failed to express conformational epitopes; (c) deletion of the first 25 N-terminal amino acids also abolished expression of conformational epitopes (without altering VLP formation) but the native conformation of this deletion mutant could be restored by the addition of the human papillomavirus type 11 N terminus. These results demonstrate that VLP formation and conformational epitope expression can be dissociated and that the L1 N terminus has a critical role in protein folding. In addition, it appears that correct L1 protein folding is not dependent upon the nucleoplasmic environment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747722     DOI: 10.1099/0022-1317-79-9-2137

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.

Authors:  Michael Berg; Julie Difatta; Egbert Hoiczyk; Richard Schlegel; Gary Ketner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

2.  Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.

Authors:  H Yuan; P A Estes; Y Chen; J Newsome; V A Olcese; R L Garcea; R Schlegel
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.

Authors:  Thomas O Kohl; Inga I Hitzeroth; Neil D Christensen; Edward P Rybicki
Journal:  BMC Biotechnol       Date:  2007-09-12       Impact factor: 2.563

4.  Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope.

Authors:  Vanessa A Olcese; Yan Chen; Richard Schlegel; Hang Yuan
Journal:  BMC Microbiol       Date:  2004-07-19       Impact factor: 4.465

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.